
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES214
A subgroup analysis suggested that in the population of patients with clinically evident CVD
(symptomatic) the combination of clopidogrel plus aspirin was significantly beneficial in
comparison with placebo plus aspirin with respect to the primary efficacy endpoint. (Among
the 12,153 symptomatic patients, there was a marginally significant reduction in the primary
endpoint with aspiring plus clopidogrel. See table 15.3.) Level 1++

[@Bhatt_2006]

